Jinfeng Medical-B surged over 6% in the morning; its self-developed "Three-in-One" surgical robot platform has received NMPA approval for market listing.

Jingfeng Medical-B (02675) surged over 6% intraday. As of the latest report, the stock price increased by 6.29%, currently trading at HKD 57.50, with a turnover of HKD 23.7775 million.

According to Jingfeng Medical’s official WeChat account, recently, the world’s first and currently the only “Porous + Single-Port + Remote” integrated surgical robot platform, independently developed by Jingfeng Medical, has officially received approval for market listing from the National Medical Products Administration (NMPA). This marks a key breakthrough for Jingfeng Medical in launching the industry’s first “Three-in-One” minimally invasive surgical innovation solution, completing the transition from technological exploration and product deployment to regulatory approval. It also signifies a major milestone in the development of high-end surgical robots in China, advancing platform innovation, systematic integration, and clinical application expansion.

As China’s first and the world’s second company to obtain registration approval for both porous and single-port endoscopic surgical robots and natural orifice transluminal endoscopic surgery (NOTES) robots, Jingfeng Medical has built a comprehensive product matrix. With the official approval of the “Three-in-One” platform by the NMPA, the company will continue to deepen the dual-driven approach of remote operation and artificial intelligence.

(Edited by Liu Chang)

【Disclaimer】This article reflects only the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions in this article and does not provide any explicit or implicit guarantees regarding the accuracy, reliability, or completeness of the content. Readers are advised to use this information for reference only and bear all responsibilities themselves. Email: news_center@staff.hexun.com